Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effects of Primary Physician Presence in AI-Synthesized SGLT2 Inhibitor Educational Videos for Heart Failure (AI-PRESENCE HF)

9 de novembro de 2026 atualizado por: In-Cheol Kim, Keimyung University Dongsan Medical Center

Effects of Primary Physician Presence in SGLT2 Inhibitor-Focused Heart Failure Educational Videos During Outpatient Waiting Time on Patient Satisfaction and Educational Effectiveness : A Randomized 2x2 Factorial Study

The purpose of this study is to evaluate the effect of the primary attending physician's presence in educational videos on patient satisfaction and educational effectiveness.

Visão geral do estudo

Descrição detalhada

The videos, generated using AI technology, focus on SGLT2 inhibitors and are provided to heart failure patients during their outpatient clinic waiting time.

In this single-center, randomized, 2x2 factorial study, participants will be assigned to one of four groups based on two factors: the specific doctor featured in the video (Doctor A vs. Doctor B) and the physician's role presentation (presented as the patient's actual attending physician vs. a non-attending general cardiologist).

All participants will watch the assigned educational video during their waiting time and then proceed with their scheduled outpatient consultation. After the consultation, participants will complete a single survey. The survey will assess overall patient satisfaction, the perceived usefulness of the education, and the objective understanding of the video's key messages regarding heart failure management and SGLT2 inhibitors.

Tipo de estudo

Intervencional

Inscrição (Estimado)

150

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Incheol Kim, MD
  • Número de telefone: +82-53-258-4625
  • E-mail: kimic@dsmc.or.kr

Locais de estudo

      • Daegu, Coréia do Sul, 42601
        • Recrutamento
        • Keimyung University Dongsan Medical Center
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

19 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Adults aged 19 years or older.
  • Patients diagnosed with heart failure or those visiting the cardiology outpatient clinic with suspected heart failure symptoms (e.g., dyspnea, edema).
  • Patients currently taking or scheduled to be prescribed SGLT2 inhibitors for the treatment of heart failure.
  • Patients who are able to watch the educational video during the outpatient waiting time and complete the survey after the consultation.
  • Patients who fully understand the purpose and procedures of this study and voluntarily provide written informed consent.

Exclusion Criteria:

  • Patients who do not understand the contents of this study or do not consent to the study due to cognitive decline, etc.
  • Patients with expected acute exacerbation of heart failure or a life expectancy of 1 year or less.
  • Patients who have difficulty watching the video due to visual or hearing impairments.
  • Patients scheduled for heart failure-related surgery or procedures.
  • Patients who are currently participating in, or have participated in within the past 6 months, another intervention study related to heart failure education.
  • Other patients deemed inappropriate for study participation by the investigator.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição fatorial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Doctor A - Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as their primary physician.

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Outros nomes:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Comparador Ativo: Doctor A - Non-Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as a general cardiologist (non-attending).

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Outros nomes:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Experimental: Doctor B - Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as their primary physician.

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Outros nomes:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Comparador Ativo: Doctor B - Non-Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as a general cardiologist (non-attending).

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Outros nomes:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Patient Satisfaction Score
Prazo: Immediately after the outpatient clinic visit (Day 0)

Patient satisfaction regarding the positive impact and helpfulness of the educational video on the subsequent outpatient consultation process. It is assessed using a 5-point Likert scale ranging from 1 to 5. A higher score indicates a higher level of patient satisfaction.

Immediately after the outpatient clinic visit (Day 0)
Educational Usefulness Score
Prazo: Immediately after the outpatient clinic visit (Day 0)

The perceived usefulness of the educational video in understanding heart failure treatment methods, specifically the role, effects, and precautions of SGLT2 inhibitors. It is assessed using a 5-point Likert scale ranging from 1 to 5. A higher score indicates greater perceived educational usefulness and understanding.

Immediately after the outpatient clinic visit (Day 0)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Educational Content Delivery Effectiveness Score
Prazo: Immediately after the outpatient clinic visit (Day 0)

An objective assessment of the patient's understanding of the video's key messages, such as heart failure management and SGLT2 inhibitor information. It is evaluated based on the number of correct answers to 4 multiple-choice questions derived directly from the video's core content. The total score ranges from 0 to 4, where 1 point is awarded for each correct answer. A higher score indicates a better understanding and a higher level of correct knowledge acquisition.

Immediately after the outpatient clinic visit (Day 0)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

21 de agosto de 2026

Conclusão Primária (Estimado)

31 de julho de 2027

Conclusão do estudo (Estimado)

31 de julho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

9 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de novembro de 2026

Primeira postagem (Real)

16 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 2026-06-008

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever